Developer docs
API playgroundTry for free, no card

Search company profiles

Cantargia

Full company profile

uuid00025uj

Namestring
Cantargia
Legal namestring
Cantargia AB
Websiteurl
cantargia.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Cantargia AB is a Swedish clinical-stage biotechnology company founded in 2010 and headquartered in Lund, Sweden, developing antibody-based therapeutics that target Interleukin-1 Receptor Accessory Protein (IL1RAP) for the treatment of cancer and serious inflammatory diseases. The company's pipeline is built around an IL1RAP platform that has generated multiple antibody programs with distinct mechanisms of action: lead candidate nadunolimab (CAN04) is an anti-IL1RAP antibody that induces antibody-dependent cellular cytotoxicity (ADCC) and blocks IL-1α and IL-1β signaling, with clinical activity demonstrated in approximately 300 patients across solid tumor indications including pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The company received US FDA Fast Track Designation for nadunolimab in metastatic PDAC with high IL1RAP expression in June 2025. Additional programs include CAN10 (a second-generation IL1RAP antibody blocking IL-1, IL-33 and IL-36 signaling, divested to Otsuka Pharmaceutical in September 2025 for up to USD 613 million), CAN14 (a bispecific antibody in preclinical development), and early-stage CANxx programs exploring antibody-drug conjugate modalities.

Cantargia operates as a clinical-stage company with no commercialized products and therefore no product pricing or product revenue. Its revenue model is based on out-licensing and milestone payments from pharmaceutical partners, as demonstrated by the Otsuka transaction for CAN10 which generated SEK 280 million in 2025 net sales. Clinical development is conducted primarily through investigator-initiated trials at major cancer centers including Mount Sinai, MD Anderson, Sylvester Comprehensive Cancer Center, and Herlev Hospital, rather than through company-sponsored pivotal trials. The company is publicly listed on Nasdaq Stockholm under ticker CANTA, with approximately 281.9 million shares outstanding following the June 2026 rights issue. Capital is raised through periodic rights issues (notably approximately SEK 250 million in 2022 and SEK 75 million in June 2026) and a SEK 50 million loan facility from Fenja Capital II A/S signed in June 2025.

For 2025, the company reported net sales of SEK 316.7 million and an operating profit of SEK 154.1 million, reversing the operating loss of SEK 168.6 million reported in 2024. Cash and cash equivalents stood at SEK 281.8 million at year-end 2025, compared to SEK 33.0 million at year-end 2024. The company's strategic focus is on advancing nadunolimab in pancreatic cancer and expanding into hematological malignancies (MDS, AML), colorectal cancer, and lung cancer prevention, while leveraging the IL1RAP platform for additional pipeline opportunities. Leadership was refreshed in 2025-2026 with the appointment of Dr. Hilde Steineger as CEO and Dr. Wolfram Dempke as CMO.

Short descriptiontext

Cantargia AB is a Swedish clinical-stage biotechnology company developing antibody-based therapeutics targeting IL1RAP for the treatment of solid tumors, hematological malignancies, and inflammatory diseases, with lead candidate nadunolimab in pancreatic and lung cancer clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, oncology drug development, IL1RAP targeting, clinical-stage biotechnology, immuno-oncology research
NAICS code1 code
  • Other Ambulatory Health Care Services6219
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Biopharmaceutical Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue generated through licensing deals and milestone payments from pharmaceutical partners. The CAN10 acquisition by Otsuka Pharmaceutical generated USD 33 million upfront with potential additional milestone payments up to USD 580 million and tiered royalties up to double digits on global sales.

cantargia.com
2Equity Financing
TypeOne Time License
Description

Rights issues and capital raises to fund clinical development. Cantargia completed a rights issue of approximately SEK 124 million in 2026 and previously raised approximately SEK 250 million in 2022.

news.cision.com
3Loan Facility
TypeManaged Services
Description

SEK 50 million loan agreement with Fenja Capital II A/S signed in June 2025, providing operational flexibility and extending cash runway into 2026.

pharmiweb.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1nadunolimab (CAN04)
Description

Anti-IL1RAP antibody being studied clinically in combination with chemotherapy for pancreatic cancer and non-small cell lung cancer

cantargia.com
+2 more records
Core offering1 text field

Cantargia is a clinical-stage biotechnology company developing antibody-based therapeutics that target IL1RAP (Interleukin-1 Receptor Accessory Protein) for the treatment of cancer and serious inflammatory/autoimmune diseases. Its lead asset, nadunolimab (CAN04), is an anti-IL1RAP antibody in clinical development for pancreatic cancer, non-small cell lung cancer, and hematological malignancies, while the IL1RAP platform has supported additional programs including CAN10, CAN14, and CANxx.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Median overall survival of 14.2 months in PDAC patients with high IL1RAP expression treated with nadunolimab + gemcitabine/nab-paclitaxel
+3 more records
Product overview1 text field

Cantargia is a Swedish biotech company developing antibody-based treatments targeting IL1RAP. The company operates a platform-based model with its IL1RAP technology as the foundation. The core product is nadunolimab (CAN04), an anti-IL1RAP antibody in clinical development for solid tumors including pancreatic cancer and non-small cell lung cancer. The portfolio includes CAN14 (bispecific antibody for inflammation), CANxx (early ADC-based research), and the now-acquired CAN10 program. Following the September 2025 acquisition of CAN10 by Otsuka Pharmaceutical, Cantargia retains its focus on oncology while the platform continues to support multiple pipeline candidates.

Product and service4 records
1Nadunolimab (CAN04)
CategoryOncology Therapeutic Antibody
2CAN10
CategoryAnti-inflammatory Antibody Program
3CAN14
CategoryBispecific Antibody Program
4IL1RAP Platform
CategoryAntibody Discovery Platform
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Investigator-initiated Phase 2 clinical trial in lung cancer prevention study (NCT07284485) in collaboration with Drs. Robert Samstein, Thomas Marron and Miriam Merad. Nadunolimab being evaluated as preventive treatment in current/former smokers with high-risk lung nodules.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-17
Description

Investigator-initiated Phase 1b/2a trial evaluating nadunolimab in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Led by Dr. Gautam Borthakur, Professor of leukemia. Study evaluating nadunolimab with azacitidine or azacitidine/venetoclax.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-23
Description

Investigator-initiated study in metastatic microsatellite stable colorectal cancer (MSS CRC). Dr. Dan Fang leading Phase 1b/2 trial (NCT07281716) investigating nadunolimab with checkpoint inhibitors in up to 24 patients. Research collaboration generating preclinical data showing nadunolimab effects in CRC models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Collaboration with Dr. Jashodeep Datta's group on PDAC research. Data presented at AACR 2025 showing IL1RAP's role in PDAC microenvironment and nadunolimab's effects in preclinical KRAS-mutated PDAC models. Strong scientific rationale for targeting IL1RAP in pancreatic cancer.

5Herlev Hospital, Copenhagen
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Research collaboration on tumor cell expression of IL1RAP in pancreatic cancer. Data demonstrating that high IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while these patients showed longest survival when treated with nadunolimab combination therapy.

cantargia.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-09-11
Description

Otsuka acquired the CAN10 IL1RAP antibody program from Cantargia for USD 33 million upfront payment, with potential additional milestone payments up to USD 580 million comprising development, regulatory and commercial milestones. Tiered royalties up to double digits on global sales are applicable. Otsuka will direct and perform all future development, apply for regulatory approvals and exclusively carry out manufacturing and commercialization worldwide.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-19
Description

Research collaboration generating preclinical results showing CAN10's potential to inhibit vascular inflammation. Study published in Journal of the American Heart Association demonstrating IL1RAP-targeting antibodies can block IL-1, IL-33, and IL-36 induced inflammatory responses in endothelial cells.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing therapeutics targeting the IL-1 pathway (rilonacept, mavrilimumab, vixarelimab), making it one of the most directly comparable peers to Cantargia's IL1RAP-targeting approach. Similar focus on inflammation and immunology indications.

TypeDirect peer
Description

Biotech with established PDAC development program (PEGPH20/Enhanze platform) and oncology focus. Directly comparable as a clinical-stage company targeting pancreatic cancer indications.

TypeDirect peer
Description

Clinical-stage oncology biotech developing a Probody antibody platform for cancer therapeutics, with multiple programs in solid tumors. Comparable as a platform-based antibody developer with similar stage and modality focus.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific immunostimulatory antibodies (ISACs) for cancer. Similar modality (antibody-based), oncology focus, and clinical-stage profile as Cantargia.

TypeDirect peer
Description

Clinical-stage biotech developing multiple antibody-based therapeutics for cancer (including bispecifics and ADCs). Comparable in technology platform approach, oncology focus, and clinical development stage.

TypeDirect peer
Description

Clinical-stage biotech developing antibody-drug conjugates (ADCs) for cancer, with a Dolasynthen platform. Comparable as Cantargia explores ADC approaches (CANxx) within its IL1RAP platform.

TypeRegional player
Description

Swedish-headquartered specialty biotech with Kineret (anakinra, an IL-1 receptor antagonist) in its portfolio. Comparable as a Swedish biotech with established IL-1 pathway products, providing regional and therapeutic context.

TypeBroad incumbent
Description

Global biopharmaceutical company with deep oncology pipeline (durvalumab for multiple cancers, Tagrisso, Lynparza) and respiratory/inflammation portfolio. Comparable as a potential strategic partner or acquirer; Cantargia's new CMO has prior leadership experience at AstraZeneca.

9Bristol-Myers Squibb
TypeBroad incumbent
Description

Major oncology company with multiple antibody therapeutics (Opdivo, Yervoy, others) and deep PDAC development programs. Comparable as a potential large pharma partner/acquirer; Cantargia's CMO also has prior leadership experience at BMS.

TypeBroad incumbent
Description

Global specialty pharma with oncology focus (Somatuline, Onivyde for PDAC, Cabometyx). Comparable as an established oncology player with pancreatic cancer franchise, providing potential partnership or acquisition interest.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cantargia

Biopharmaceutical Oncology Therapeuticscantargia.com

Cantargia AB is a Swedish clinical-stage biotechnology company developing antibody-based therapeutics targeting IL1RAP for the treatment of solid tumors, hematological malignancies, and inflammatory diseases, with lead candidate nadunolimab in pancreatic and lung cancer clinical trials.

What Cantargia does

Cantargia AB is a Swedish clinical-stage biotechnology company founded in 2010 and headquartered in Lund, Sweden, developing antibody-based therapeutics that target Interleukin-1 Receptor Accessory Protein (IL1RAP) for the treatment of cancer and serious inflammatory diseases. The company's pipeline is built around an IL1RAP platform that has generated multiple antibody programs with distinct mechanisms of action: lead candidate nadunolimab (CAN04) is an anti-IL1RAP antibody that induces antibody-dependent cellular cytotoxicity (ADCC) and blocks IL-1α and IL-1β signaling, with clinical activity demonstrated in approximately 300 patients across solid tumor indications including pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The company received US FDA Fast Track Designation for nadunolimab in metastatic PDAC with high IL1RAP expression in June 2025. Additional programs include CAN10 (a second-generation IL1RAP antibody blocking IL-1, IL-33 and IL-36 signaling, divested to Otsuka Pharmaceutical in September 2025 for up to USD 613 million), CAN14 (a bispecific antibody in preclinical development), and early-stage CANxx programs exploring antibody-drug conjugate modalities.

Cantargia operates as a clinical-stage company with no commercialized products and therefore no product pricing or product revenue. Its revenue model is based on out-licensing and milestone payments from pharmaceutical partners, as demonstrated by the Otsuka transaction for CAN10 which generated SEK 280 million in 2025 net sales. Clinical development is conducted primarily through investigator-initiated trials at major cancer centers including Mount Sinai, MD Anderson, Sylvester Comprehensive Cancer Center, and Herlev Hospital, rather than through company-sponsored pivotal trials. The company is publicly listed on Nasdaq Stockholm under ticker CANTA, with approximately 281.9 million shares outstanding following the June 2026 rights issue. Capital is raised through periodic rights issues (notably approximately SEK 250 million in 2022 and SEK 75 million in June 2026) and a SEK 50 million loan facility from Fenja Capital II A/S signed in June 2025.

For 2025, the company reported net sales of SEK 316.7 million and an operating profit of SEK 154.1 million, reversing the operating loss of SEK 168.6 million reported in 2024. Cash and cash equivalents stood at SEK 281.8 million at year-end 2025, compared to SEK 33.0 million at year-end 2024. The company's strategic focus is on advancing nadunolimab in pancreatic cancer and expanding into hematological malignancies (MDS, AML), colorectal cancer, and lung cancer prevention, while leveraging the IL1RAP platform for additional pipeline opportunities. Leadership was refreshed in 2025-2026 with the appointment of Dr. Hilde Steineger as CEO and Dr. Wolfram Dempke as CMO.

Cantargia firmographics

Firmographics
Name
Cantargia
Legal name
Cantargia AB
Website
https://cantargia.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Cantargia AB is a Swedish clinical-stage biotechnology company developing antibody-based therapeutics targeting IL1RAP for the treatment of solid tumors, hematological malignancies, and inflammatory diseases, with lead candidate nadunolimab in pancreatic and lung cancer clinical trials.
Ownership category
akta.pro rank

Where Cantargia is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Cantargia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: Revenue generated through licensing deals and milestone payments from pharmaceutical partners. The CAN10 acquisition by Otsuka Pharmaceutical generated USD 33 million upfront with potential additional milestone payments up to USD 580 million and tiered royalties up to double digits on global sales.
  2. Equity Financing: Rights issues and capital raises to fund clinical development. Cantargia completed a rights issue of approximately SEK 124 million in 2026 and previously raised approximately SEK 250 million in 2022.
  3. Loan Facility: SEK 50 million loan agreement with Fenja Capital II A/S signed in June 2025, providing operational flexibility and extending cash runway into 2026.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Cantargia product offering

Product offering

Core offering

Cantargia is a clinical-stage biotechnology company developing antibody-based therapeutics that target IL1RAP (Interleukin-1 Receptor Accessory Protein) for the treatment of cancer and serious inflammatory/autoimmune diseases. Its lead asset, nadunolimab (CAN04), is an anti-IL1RAP antibody in clinical development for pancreatic cancer, non-small cell lung cancer, and hematological malignancies, while the IL1RAP platform has supported additional programs including CAN10, CAN14, and CANxx.

Product overview

Cantargia is a Swedish biotech company developing antibody-based treatments targeting IL1RAP. The company operates a platform-based model with its IL1RAP technology as the foundation. The core product is nadunolimab (CAN04), an anti-IL1RAP antibody in clinical development for solid tumors including pancreatic cancer and non-small cell lung cancer. The portfolio includes CAN14 (bispecific antibody for inflammation), CANxx (early ADC-based research), and the now-acquired CAN10 program. Following the September 2025 acquisition of CAN10 by Otsuka Pharmaceutical, Cantargia retains its focus on oncology while the platform continues to support multiple pipeline candidates.

Differentiator

Problem solved

Functional benefit

Brands

  • nadunolimab (CAN04): Anti-IL1RAP antibody being studied clinically in combination with chemotherapy for pancreatic cancer and non-small cell lung cancer
  • CAN14
  • CANxx

Products and services

  • Nadunolimab (CAN04)
  • CAN10
  • CAN14
  • IL1RAP Platform

Quantifiable outcome

  • Median overall survival of 14.2 months in PDAC patients with high IL1RAP expression treated with nadunolimab + gemcitabine/nab-paclitaxel
  • +3 more outcomes

Companies that use Cantargia

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Cantargia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cantargia partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Mount Sinai Tisch Cancer CentercoreStrategic or Co-development Partner · 10 June 2026Investigator-initiated Phase 2 clinical trial in lung cancer prevention study (NCT07284485) in collaboration with Drs. Robert Samstein, Thomas Marron and Miriam Merad. Nadunolimab being evaluated as preventive treatment in current/former smokers with high-risk lung nodules.
  • The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development Partner · 17 April 2026Investigator-initiated Phase 1b/2a trial evaluating nadunolimab in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Led by Dr. Gautam Borthakur, Professor of leukemia. Study evaluating nadunolimab with azacitidine or azacitidine/venetoclax.
  • Icahn School of Medicine at Mount SinaicoreStrategic or Co-development Partner · 23 January 2026Investigator-initiated study in metastatic microsatellite stable colorectal cancer (MSS CRC). Dr. Dan Fang leading Phase 1b/2 trial (NCT07281716) investigating nadunolimab with checkpoint inhibitors in up to 24 patients. Research collaboration generating preclinical data showing nadunolimab effects in CRC models.
  • Sylvester Comprehensive Cancer Center, University of MiamicoreStrategic or Co-development Partner · 1 October 2025Collaboration with Dr. Jashodeep Datta's group on PDAC research. Data presented at AACR 2025 showing IL1RAP's role in PDAC microenvironment and nadunolimab's effects in preclinical KRAS-mutated PDAC models. Strong scientific rationale for targeting IL1RAP in pancreatic cancer.
  • Herlev Hospital, CopenhagenminorStrategic or Co-development Partner · 1 October 2025Research collaboration on tumor cell expression of IL1RAP in pancreatic cancer. Data demonstrating that high IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while these patients showed longest survival when treated with nadunolimab combination therapy.
  • Otsuka Pharmaceutical Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 11 September 2025Otsuka acquired the CAN10 IL1RAP antibody program from Cantargia for USD 33 million upfront payment, with potential additional milestone payments up to USD 580 million comprising development, regulatory and commercial milestones. Tiered royalties up to double digits on global sales are applicable. Otsuka will direct and perform all future development, apply for regulatory approvals and exclusively carry out manufacturing and commercialization worldwide.
  • Örebro UniversityminorStrategic or Co-development Partner · 19 May 2025Research collaboration generating preclinical results showing CAN10's potential to inhibit vascular inflammation. Study published in Journal of the American Heart Association demonstrating IL1RAP-targeting antibodies can block IL-1, IL-33, and IL-36 induced inflammatory responses in endothelial cells.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Cantargia competitors and assessment

Company assessment

Direct peers

  • Kiniksa Pharmaceuticals: Clinical-stage biotech developing therapeutics targeting the IL-1 pathway (rilonacept, mavrilimumab, vixarelimab), making it one of the most directly comparable peers to Cantargia's IL1RAP-targeting approach. Similar focus on inflammation and immunology indications.
  • Halozyme Therapeutics: Biotech with established PDAC development program (PEGPH20/Enhanze platform) and oncology focus. Directly comparable as a clinical-stage company targeting pancreatic cancer indications.
  • CytomX Therapeutics: Clinical-stage oncology biotech developing a Probody antibody platform for cancer therapeutics, with multiple programs in solid tumors. Comparable as a platform-based antibody developer with similar stage and modality focus.
  • Bolt Biotherapeutics: Clinical-stage biotech developing bispecific immunostimulatory antibodies (ISACs) for cancer. Similar modality (antibody-based), oncology focus, and clinical-stage profile as Cantargia.
  • Macrogenics: Clinical-stage biotech developing multiple antibody-based therapeutics for cancer (including bispecifics and ADCs). Comparable in technology platform approach, oncology focus, and clinical development stage.
  • Mersana Therapeutics: Clinical-stage biotech developing antibody-drug conjugates (ADCs) for cancer, with a Dolasynthen platform. Comparable as Cantargia explores ADC approaches (CANxx) within its IL1RAP platform.

Regional players

  • Swedish Orphan Biovitrum (Sobi): Swedish-headquartered specialty biotech with Kineret (anakinra, an IL-1 receptor antagonist) in its portfolio. Comparable as a Swedish biotech with established IL-1 pathway products, providing regional and therapeutic context.

Broad incumbents

  • AstraZeneca: Global biopharmaceutical company with deep oncology pipeline (durvalumab for multiple cancers, Tagrisso, Lynparza) and respiratory/inflammation portfolio. Comparable as a potential strategic partner or acquirer; Cantargia's new CMO has prior leadership experience at AstraZeneca.
  • Bristol-Myers Squibb: Major oncology company with multiple antibody therapeutics (Opdivo, Yervoy, others) and deep PDAC development programs. Comparable as a potential large pharma partner/acquirer; Cantargia's CMO also has prior leadership experience at BMS.
  • Ipsen: Global specialty pharma with oncology focus (Somatuline, Onivyde for PDAC, Cabometyx). Comparable as an established oncology player with pancreatic cancer franchise, providing potential partnership or acquisition interest.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cantargia social profiles

Digital presence

Cantargia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cantargia leadership team

Management profile

Number of profiles

Profiles1 record

Cantargia funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cantargia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cantargia

What does Cantargia do?

Cantargia is a clinical-stage biotechnology company developing antibody-based therapeutics that target IL1RAP (Interleukin-1 Receptor Accessory Protein) for the treatment of cancer and serious inflammatory/autoimmune diseases. Its lead asset, nadunolimab (CAN04), is an anti-IL1RAP antibody in clinical development for pancreatic cancer, non-small cell lung cancer, and hematological malignancies, while the IL1RAP platform has supported additional programs including CAN10, CAN14, and CANxx.

Is Cantargia a public or private company?

Cantargia is a public company. It is classified as public and is currently operating.

When was Cantargia founded?

Cantargia was founded in 2010. It employs 11 to 50 people.

Where is Cantargia based?

Cantargia is headquartered in Lund, Sweden, in the Europe region.

How does Cantargia make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are equity Financing and loan Facility.

Who are Cantargia's main competitors?

Direct peers on record are Kiniksa Pharmaceuticals, Halozyme Therapeutics, CytomX Therapeutics, Bolt Biotherapeutics, Macrogenics and Mersana Therapeutics. Swedish Orphan Biovitrum (Sobi) is listed as a regional player. Broad incumbents are AstraZeneca, Bristol-Myers Squibb and Ipsen.

Does Cantargia have an API?

No public API is recorded for Cantargia.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comCantargia at Stifel 2026 healthcare conference: pipeline gains tractionCantargia presented its IL1RAP-based drug platform at the Stifel 2026 Healthcare Conference, citing early clinical signals in MDS and AML and pancreatic cancer. The company highlighted a $613 million Otsuka deal and a planned pancreatic cancer combination study in Q1 2025, with top-line MDS/AML data expected by mid-2027.The future of tradingCantargia Announces Annual General MeetingCantargia will hold its annual general meeting on May 25, 2027, at Ideon Gateway in Lund, Sweden. Proposals will cover board elections, director remuneration, and auditor appointment and remuneration, with the nomination committee possibly proposing changes to appointment principles.The future of tradingCantargia appoints Monic Stuart as chief medical officerCantargia appointed Monic Stuart as chief medical officer, effective immediately. She will lead nadunolimab's clinical development across blood cancers and solid tumors, bringing over 20 years of oncology drug development experience, including senior leadership at Genentech and Geron.TradingViewCantargia AB (publ) (CANTA) Preclinical Data Back Nadunolimab+RASi, Phase 1b/2a PlannedCantargia reported preclinical data from Fred Hutch showing nadunolimab plus a RAS inhibitor reduced tumor burden and immune suppression in pancreatic ductal adenocarcinoma models. The company plans a Phase 1b/2a trial, targeting the basal-like PDAC subtype, with safety and early efficacy signals needed for a catalyst.TradingViewCantargia Highlights Preclinical Data at AACR Supporting Nadunolimab in Combination with RAS Inhibition in PDACCantargia presented preclinical data at AACR showing nadunolimab combined with a RAS inhibitor reduces tumor burden and immune suppression in pancreatic ductal adenocarcinoma. The combination targets HMGA2-driven IL-1 signaling, which drives immunosuppression in basal-like PDAC. Cantargia plans a Phase 1b/2a study of the combination.MorningstarCantargia Highlights Preclinical Data at AACR Supporting Nadunolimab in Combination with RAS Inhibition in PDACCantargia presented preclinical data at AACR showing nadunolimab combined with a RAS inhibitor reduces tumor burden and reshapes the tumor microenvironment in pancreatic ductal adenocarcinoma. The combination targets non-overlapping biology, supporting a planned Phase 1b/2a study. The poster focused on the basal-like subtype with HMGA2 expression.Investing.comCantargia at H.C. Wainwright conference: IL1RAP data in focus By Investing.comCantargia presented its IL1RAP-focused oncology programs at the H.C. Wainwright conference, highlighting nadunolimab's activity in pancreatic cancer and MDS/AML. The company cited a $613 million potential deal with Otsuka and upcoming ASH data for its MDS/AML program. It plans a Phase I-B study combining nadunolimab with daraxonrasib in pancreatic cancer starting in Q1 2025.BioSpaceCantargia to Participate in Upcoming September 2026 Investor ConferencesCantargia AB announced that its CEO Hilde Steineger will present at three investor conferences in September 2026, including H.C. Wainwright, Biostock, and the European MidCap Event. The company's antibody-based treatments for cancer and autoimmune diseases are also highlighted.Investing.comCantargia Q2 2026 slides: cash runway extends, MDS remissions shine By Investing.comCantargia AB raised SEK 132 million through a rights issue and loan facility, extending its cash runway through mid-2028 while reporting complete remissions in all evaluable high-risk myelodysplastic syndrome patients in an ongoing trial. The company also completed Phase 1b of its nadunolimab study at MD Anderson Cancer Center and outlined plans for a new combination therapy trial with daraxonrasib in pancreatic cancer. Operating expenses declined significantly as the biotech scaled back certain activities following the divestment of CAN10 to Otsuka.